E C Hirsch

Summary

Country: France

Publications

  1. doi request reprint Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Etienne C Hirsch
    INSERM, UMRS 975, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, Experimental Therapeutics of Neurodegeneration, Paris, France
    Lancet Neurol 8:382-97. 2009
  2. ncbi request reprint Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin
    Karine Parain
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    Brain Res 984:224-32. 2003
  3. pmc Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease
    Carine Karachi
    Universite Pierre et Marie Curie Paris 6, CR Icm, UMR S975, Paris, France
    J Clin Invest 120:2745-54. 2010
  4. pmc DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease
    Kiyoka Kinugawa
    CNRS, UMR 7225, Experimental Therapeutics of Neurodegeneration, Paris, France
    J Neuroinflammation 10:82. 2013
  5. ncbi request reprint [Future drug targets for Parkinson's disease]
    Etienne C Hirsch
    INSERM UMR 975, CNRS UMR 7225, Universite Pierre et Marie Curie Paris 06, institut du cerveau et de la moelle épinière, Hopital de la Salpetriere, Paris
    Bull Acad Natl Med 196:1369-77; discussion 1377-9. 2012
  6. doi request reprint Iron transport in Parkinson's disease
    E C Hirsch
    Université Pierre and Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de Moelle épinière, UMR S975, Paris, France
    Parkinsonism Relat Disord 15:S209-11. 2009
  7. doi request reprint Neuroinflammation in Parkinson's disease
    Etienne C Hirsch
    INSERM, UMR_S975, CRicm, Experimental Therapeutics of Neurodegeneration, F 75013, Paris, France
    Parkinsonism Relat Disord 18:S210-2. 2012
  8. ncbi request reprint Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
    A Hartmann
    INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 76:1785-93. 2001
  9. ncbi request reprint Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients
    C Francois
    INSERM U289, Mécanismes et Conséquences de la Mort Neuronale, Hopital de la Salpetriere, 75013 Paris, France
    J Comp Neurol 425:121-9. 2000
  10. ncbi request reprint Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia
    A Mouatt-Prigent
    INSERM U 289 Neurology and Experimental Therapeutics, Hopital de la Salpetriere, Paris, France
    J Neural Transm 111:1209-18. 2004

Collaborators

Detail Information

Publications49

  1. doi request reprint Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Etienne C Hirsch
    INSERM, UMRS 975, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, Experimental Therapeutics of Neurodegeneration, Paris, France
    Lancet Neurol 8:382-97. 2009
    ....
  2. ncbi request reprint Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin
    Karine Parain
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    Brain Res 984:224-32. 2003
    ..This suggests that nicotine and low exposure to cigarette smoke may have a neuroprotective effect on the dopaminergic nigrostriatal system by an as yet unknown mechanism...
  3. pmc Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease
    Carine Karachi
    Universite Pierre et Marie Curie Paris 6, CR Icm, UMR S975, Paris, France
    J Clin Invest 120:2745-54. 2010
    ..Our data therefore reveal that the cholinergic neurons of the PPN play a central role in controlling gait and posture and represent a possible target for pharmacological treatment of gait disorders in PD...
  4. pmc DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease
    Kiyoka Kinugawa
    CNRS, UMR 7225, Experimental Therapeutics of Neurodegeneration, Paris, France
    J Neuroinflammation 10:82. 2013
    ..Whether such a developmental CD11b/DAP12 pathway could be reactivated in a pathological context such as PD and play a role in microglia-induced DN cell death is a tantalizing hypothesis that we wished to test in this study...
  5. ncbi request reprint [Future drug targets for Parkinson's disease]
    Etienne C Hirsch
    INSERM UMR 975, CNRS UMR 7225, Universite Pierre et Marie Curie Paris 06, institut du cerveau et de la moelle épinière, Hopital de la Salpetriere, Paris
    Bull Acad Natl Med 196:1369-77; discussion 1377-9. 2012
    ..This review examines the mechanisms of neuronal degeneration in Parkinson's disease, new targets for neuroprotection, and the mechanisms causing symptoms resistant to current treatments...
  6. doi request reprint Iron transport in Parkinson's disease
    E C Hirsch
    Université Pierre and Marie Curie Paris 6, Centre de Recherche de l Institut du Cerveau et de Moelle épinière, UMR S975, Paris, France
    Parkinsonism Relat Disord 15:S209-11. 2009
    ..A mutation in DMT1 that impairs iron transport protected rodents against parkinsonism-inducing neurotoxins MPTP and 6-hydroxydopamine (6-OHDA). This study supports a critical role for DMT1 in iron-mediated neurodegeneration in PD...
  7. doi request reprint Neuroinflammation in Parkinson's disease
    Etienne C Hirsch
    INSERM, UMR_S975, CRicm, Experimental Therapeutics of Neurodegeneration, F 75013, Paris, France
    Parkinsonism Relat Disord 18:S210-2. 2012
    ..Altogether, neuroinflammatory processes might represent a target for neuroprotection in PD...
  8. ncbi request reprint Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
    A Hartmann
    INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 76:1785-93. 2001
    ....
  9. ncbi request reprint Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients
    C Francois
    INSERM U289, Mécanismes et Conséquences de la Mort Neuronale, Hopital de la Salpetriere, 75013 Paris, France
    J Comp Neurol 425:121-9. 2000
    ..The loss of dopaminergic innervation in MPTP-intoxicated monkeys and in Parkinson's disease patients may directly affect the activity of STN neurons and could participate in the hyperactivity of the structure...
  10. ncbi request reprint Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia
    A Mouatt-Prigent
    INSERM U 289 Neurology and Experimental Therapeutics, Hopital de la Salpetriere, Paris, France
    J Neural Transm 111:1209-18. 2004
    ..In HS22 cells over-expressing parkin, the distribution of the protein was similar to that observed in the perikarya of the labeled neurons...
  11. ncbi request reprint Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
    H Turmel
    INSERM U 289, , Paris, France
    Mov Disord 16:185-9. 2001
    ..We conclude that mice subchronically intoxicated with MPTP represent a valid PD model to study and manipulate caspase activation in vivo...
  12. ncbi request reprint The role of glial reaction and inflammation in Parkinson's disease
    E C Hirsch
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, 75651 Paris Cedex 13, France
    Ann N Y Acad Sci 991:214-28. 2003
    ..Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in Parkinson's disease...
  13. ncbi request reprint Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes
    M Zarate-Lagunes
    INSERM U 289, Hopital de la Salpetriere, 47 bd de l Hopital, 75013 Paris, France
    J Comp Neurol 432:184-96. 2001
    ..Thus, the degeneration of dopaminergic neurons in familial cases of Parkinson's disease with autosomal recessive transmission cannot be explained solely in terms of an alteration of this protein...
  14. ncbi request reprint FADD: A link between TNF family receptors and caspases in Parkinson's disease
    A Hartmann
    Institut National de la Santé et de la Recherche Médicale U 289, Hôpital de la Salpêtière, Paris, France
    Neurology 58:308-10. 2002
    ..8%). This decrease correlated with the known selective vulnerability of nigral DA neurons in PD, suggesting that this pathway contributes to the susceptibility of DA neurons in PD to TNF-mediated apoptosis...
  15. ncbi request reprint Neuroinflammatory processes in Parkinson's disease
    Stephane Hunot
    INSERM U289, Hopital de la Salpetriere, Paris, France
    Ann Neurol 53:S49-58; discussion S58-60. 2003
    ..In this review, we summarize and discuss the latest findings regarding neuroinflammatory aspects in PD...
  16. ncbi request reprint The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease
    P Damier
    INSERM U289, Hopital de la Salpetriere, Paris, France
    Brain 122:1437-48. 1999
    ....
  17. ncbi request reprint Preservation of midbrain catecholaminergic neurons in very old human subjects
    N Kubis
    INSERM U289 Hôpital de la Salpetrière, Paris, France
    Brain 123:366-73. 2000
    ....
  18. ncbi request reprint Dopaminergic cell group A8 in the monkey: anatomical organization and projections to the striatum
    C Francois
    INSERM U289, Mécanismes et Conséquences de la Mort Neuronale, Hopital de la Salpetriere, 75013, Paris, France
    J Comp Neurol 414:334-47. 1999
    ..In conclusion, each mesencephalic cell group projects primarily to one specific striatal region but also participates, albeit to a lesser extent, in the innervation of all the remaining striatal parts...
  19. ncbi request reprint Tremor-related activity of neurons in the 'motor' thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism
    D Guehl
    INSERM U 289 Experimental Neurology and Therapeutics, Hopital de la Salpetriere, 47 bd de l Hopital, 75651 Paris Cedex 13, France
    Eur J Neurosci 17:2388-400. 2003
    ....
  20. ncbi request reprint Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat
    C Jan
    INSERM UMR 679, Neurology and Experimental Therapeutics, Paris, France
    J Neural Transm 114:1509-17. 2007
    ....
  21. ncbi request reprint Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease
    A Mouatt-Prigent
    Institut National de la Santé et de la Recherche Médicale U289, Hopital de la Salpetriere, 75013 Paris, France
    J Comp Neurol 419:175-92. 2000
    ..These data suggest that calpain II overexpression in Parkinson's disease is not compensated for by a concomitant increase in calpastatin expression...
  22. ncbi request reprint Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease
    T Breidert
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Pitie Salpetriere, Paris, France
    J Neurochem 82:615-24. 2002
    ..Since pioglitazone affects primarily the SNpc in our model, different PPARgamma-independent mechanisms may regulate glial activation in the dopaminergic terminals compared with the dopaminergic cell bodies after acute MPTP intoxication...
  23. ncbi request reprint Nondopaminergic neurons in Parkinson's disease
    E C Hirsch
    INSERM U289, Department of Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    Adv Neurol 91:29-37. 2003
  24. ncbi request reprint Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice
    I Gourfinkel-An
    INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 86:1369-78. 2003
    ..These data, which may, in part, account for the behavioural changes seen in these animals, indicate that at 12.5 weeks of age the pathological features seen in the mice differ from those seen in humans with Huntington's disease...
  25. pmc Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease
    Vanessa Brochard
    INSERM, UMR S679, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    J Clin Invest 119:182-92. 2009
    ..Further, our data may provide a rationale for targeting the adaptive arm of the immune system as a therapeutic strategy in PD...
  26. ncbi request reprint Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter
    Andreas Hartmann
    INSERM U 289, Hopital de la Salpetriere, Paris, France
    Exp Neurol 184:561-4. 2003
  27. doi request reprint How to improve neuroprotection in Parkinson's disease?
    E C Hirsch
    INSERM U679, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    Parkinsonism Relat Disord 13:S332-5. 2007
    ..This may thus represent a therapeutic target for PD...
  28. ncbi request reprint Cloning of rat parkin cDNA and distribution of parkin in rat brain
    W J Gu
    INSERM U 289, Hopital de la Salpetriere, Paris, France
    J Neurochem 74:1773-6. 2000
    ..Thus, the role of parkin may be much more global than previously thought on the basis of genetic findings gathered in cases of early-onset parkinsonism...
  29. ncbi request reprint Glial cells and Parkinson's disease
    E C Hirsch
    INSERM U 289, Hopital de la Salpetriere, Paris, France
    J Neurol 247:II58-62. 2000
    ..This paper reviews the potentially protective or deleterious effects of glial cells in the substantia nigra of patients with Parkinson's disease...
  30. ncbi request reprint Role of activity-dependent mechanisms in the control of dopaminergic neuron survival
    Patrick P Michel
    INSERM, UMR679, Paris, France
    J Neurochem 101:289-97. 2007
    ..This review focuses on the mechanisms by which activity-dependent mechanisms might modulate dopaminergic cell survival...
  31. ncbi request reprint KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis
    Damien Toulorge
    Universite Pierre et Marie Curie PARIS6, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, Unité Mixte de Recherche S975, Paris, France
    J Neurochem 114:553-64. 2010
    ....
  32. doi request reprint Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication
    Anne Sophie Rolland
    INSERM, UMR_S975, Experimental Therapeutics of Neurodegeneration, Paris, France
    J Neurochem 110:1321-9. 2009
    ....
  33. ncbi request reprint Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism
    Anne Sophie Rolland
    INSERM, UMR679, Neurology and Experimental Therapeutics, Paris, France
    Brain 130:265-75. 2007
    ..Hypoactivity of both the basal ganglia-thalamic and cerebellar-thalamic pathways might therefore be implicated in the development of parkinsonian symptoms...
  34. ncbi request reprint Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism
    Bénédicte Salthun-Lassalle
    INSERM 679, Bâtiment Pharmacie, Hopital de la Salpetriere, 47 bd de l Hopital, 75013, Paris, France
    Mol Pharmacol 68:1214-24. 2005
    ..Together, these data further support the notion that the survival of mesencephalic DA neurons during development depends largely on excitatory inputs, which may be provided in part by tachykinins...
  35. ncbi request reprint Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro
    Carmen Henze
    INSERM U 679 former U 289, Experimental Neurology and Therapeutics, centre d investigation clinique, Hopital de la Salpetriere, Paris, France
    Neurosci Lett 383:44-8. 2005
    ..However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment...
  36. ncbi request reprint The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy
    Günter U Höglinger
    INSERM U679, Hopital de la Salpetriere, Paris, France
    J Neurochem 95:930-9. 2005
    ..Our data suggest that chronic respiratory chain dysfunction might trigger a form of neurodegeneration in which accumulation of hyperphosphorylated tau protein predominates over deposits of alpha-synuclein...
  37. doi request reprint Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid
    Daniel Alvarez-Fischer
    Institut National de la Sante et de la Recherche Medicale, Unité Mixte de Recherche S679, Paris, France
    J Neurochem 107:701-11. 2008
    ..p. route. Even under these conditions, dopaminergic cell loss was moderate (-25%) and other neurodegenerative changes characteristic of Parkinson's disease remained undetectable...
  38. ncbi request reprint Neuroinflammatory processes in Parkinson's disease
    Etienne C Hirsch
    INSERM U675, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    Parkinsonism Relat Disord 11:S9-S15. 2005
    ..Inhibition of the glial reaction and the inflammatory processes may thus represent a therapeutic target to reduce neuronal degeneration in PD...
  39. ncbi request reprint Donepezil induces a cholinergic sprouting in basocortical degeneration
    Laure Ginestet
    INSERM, UMR 679, Neurology and Experimental Therapeutics, Hopital de la Salpetriere, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Neurochem 102:434-40. 2007
    ..This suggests a neuroplastic activity of this drug and provides evidence for a potential use of donepezil as a disease modifier in neurodegenerative diseases such as AD...
  40. ncbi request reprint Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
    Baptiste A Faucheux
    INSERM, U289 and U360 et Centre de Recherches de Neurologie Neuropathologie de l Association Claude Bernard, Hopital de la Salpetriere, Paris, France
    J Neurochem 83:320-30. 2002
    ..The data of this study do not favor changes in transcription and post-transcriptional regulation of ferritin expression in Parkinson's disease and suggest a 'compartmentalized' iron accumulation...
  41. ncbi request reprint Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP
    Estelle Rousselet
    Hôpital Lariboisière AP HP, 75010, Paris, France
    Exp Neurol 177:183-92. 2002
    ....
  42. ncbi request reprint Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats
    Marie Paule Muriel
    Institut National de la Santé et de la Recherche Médicale U 289, Hopital de la Salpetriere, Paris, France
    Mov Disord 17:1174-9. 2002
    ..Ropinirole is consequently less likely to desensitize D1 dopamine receptors than levodopa and, thus, to reduce the efficacy of the treatment...
  43. ncbi request reprint Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats
    Günter U Höglinger
    INSERM U 289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    J Neurochem 84:491-502. 2003
    ....
  44. ncbi request reprint New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis
    Dominique Tande
    INSERM U679, Neurology and Experimental Therapeutics, Salpetriere Hospital, Paris, France
    Brain 129:1194-200. 2006
    ..Understanding of the molecular signals mediating this phenotypic shift might help in developing novel and elegant strategies for a cell-based therapy for Parkinson's disease that would avoid many of the drawbacks of cell transplantation...
  45. ncbi request reprint Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats
    Celine Perier
    INSERM U289, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    J Neurochem 86:1328-37. 2003
    ..Our study thus shows that lesion of the EP or STN may counteract some of the neurochemical changes induced by levodopa treatment within the striatum...
  46. ncbi request reprint The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway
    Sabine Traver
    Unité Mixte de Recherche 679, INSERM UPMC Bâtiment Pharmacie, Hopital de la Salpetriere, 47 bd de l Hopital, 75013, Paris, France
    Mol Pharmacol 70:30-40. 2006
    ..Whether similar mechanisms account for the high degree of plasticity of these neurons in the adult brain remains to be established...
  47. ncbi request reprint Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys
    Caroline Jan
    INSERM U289, Neurologie et Thérapeutique Expérimentale, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013, Paris, France
    Eur J Neurosci 18:2082-6. 2003
    ..The preservation of dopaminergic innervation of the limbic part of cerebral structures may explain the preservation of motivational processes mediated by these limbic regions in MPTP-treated monkeys...
  48. ncbi request reprint Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe
    Pierre Champy
    Experimental Neurology and Therapeutics, INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 88:63-9. 2004
    ....
  49. ncbi request reprint Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA
    Isabelle Gourfinkel-An
    INSERM U289, Hopital de la Salpetriere, Paris, France
    J Neurochem 80:466-76. 2002
    ....